• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

    11.06 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,458
    Open 11.06
    Bid (Size) 11.09 (900)
    Ask (Size) 11.70 (100)
    Prev. Close 11.06
    Today's Range 11.06 - 11.06
    52wk Range 2.210 - 18.31
    Shares Outstanding 43,614,075
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Phathom (PHAT) Q4 2025 Earnings Call Transcript ↗
    Phathom (PHAT) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings: Revenue Beat and Narrowed Losses Signal Path to Profitability ↗
    Via Chartmill

    Performance

    YTD
    -29.6%
    -29.6%
    1 Month
    -19.9%
    -19.9%
    3 Month
    -24.6%
    -24.6%
    6 Month
    -6.9%
    -6.9%
    1 Year
    +98.2%
    +98.2%

    More News

    Read More
    News headline image
    Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For October 30, 2025 ↗
    Via Benzinga
    News headline image
    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharma Shows Sales Strength, Targets 2026 Profitability ↗
    Via Benzinga
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) Shows Strong Growth and Momentum Alignment with Minervini Strategy ↗
    Via Chartmill
    News headline image
    High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) ↗
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire

    Frequently Asked Questions

    Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?
    Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market
    What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?
    The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 11.06
    When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 03/04/26 04:00 PM ET
    What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 482.37M
    How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?
    Phathom Pharmaceuticals, Inc. - Common Stock has 482M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.